Lending reports

Cytovia Therapeutics Announces Preclinical Activity of Its iPSC-Derived Natural Killer Cells (iNK) and Flex-NK™ Cell Engages at the 2022 AACR Annual Meeting | DNA RNA and Cells

Cytovia Therapeutics Announces Preclinical Activity of Its iPSC-Derived NK Cells (iNK) and Flex-NK™ Cell Engages at the 2022 AACR Annual Meeting

  • First in vivo data demonstrate anti-tumor activity of Glypican-3 (GPC3) Flex-NK™ cell Engager (CYT-303) in combination with iNK cells in an animal model of hepatocellular carcinoma (HCC)
  • Early In Vitro Data Evaluating CD38 Cell Engaging Flex-NK™ (CYT-338) Demonstrates a Favorable Profile Compared to Daratumumab

AVENTURA, FL and NATICK, MA, USA I April 8, 2022 I Cytovia Therapeutics, Inc., a biopharmaceutical company enabling natural killer (NK) cells to fight cancer through stem cell engineering and multi-species antibodies, announced today that new data it is presenting at the annual meeting of the American Association of Cancer Research in New Orleans on April 12and2022 is now available on the AACR and Cytovia websites.

“We are very pleased with Cytovia’s R&D team’s breakthrough progress towards manufacturing and preclinical validation of its two synergistic platforms,” commented Dr. Daniel Teper, CEO and President of Cytovia Therapeutics. “The data presented at the AACR supports the advancement of our primary hepatocellular carcinoma (HCC) program targeting GPC3 toward clinical trials and our differentiated multiple myeloma program targeting CD38 toward studies enabling IND. Cytovia is the first company to combine its own iPSC-derived natural killer cells (iNK) and multispecific NK cell-engaging antibodies and is building a pipeline that encompasses both hematological malignancies and solid tumors. »

“Cytovia’s GPC3-driven NK engager in combination with iPSC-derived NK cells demonstrated impressive anti-tumor activity in mice that warrants clinical development,” added Dr. Michael Friedman, Board Member of administration of Cytovia. “For the large number of patients with hepatocellular cancer who currently have such limited and poor clinical options, a novel NK engager directed against the tumor antigen is needed. This would be a welcome addition to a physician’s arming , with high potential for many combinations CYT-338 data, showing superiority over daratumumab in several in vitro tests, is equally impressive and in my opinion warrants further preclinical development.”

Highlights of posters presented at the AACR Annual Meeting

CYT-303

  • The FLEX-NKMT multifunctional tetravalent antibody CYT-303 directed against NKp46 and GPC3 demonstrated in vitro and live activity against HCC tumor targets.
  • iNK cells expressed a favorable combination of multiple activation and a few inhibitory receptors that corresponded to more potent cytolytic activity against HCC targets.
  • The combination of FLEX-NKMT and iNK platforms have demonstrated greater in vitro and live anti-tumor activity in HCC models than iNK cells alone, with a in vitro cytokine release and immune cell subset safety profile.
  • These proof-of-concept preclinical studies with CYT-303 alone or in combination with iNK cells in HCC warrant clinical development.

CYT-338

  • The FLEX-NKMT CYT-338 multifunctional binding antibody directed against NKp46 and CD38 demonstrated in vitro activity against multiple myeloma tumor targets.
  • Analysis of binding sites on CD38 indicates that CYT-338 binds to an epitope distinct from daratumumab.
  • The binding, cytokine release, cytotoxicity, and fratricidal profiles of CYT-338 were superior to those of daratumumab.
  • These data support the further development of CYT-338 as a therapeutic to target CD38-expressing multiple myeloma cells.

For more details on in-person poster presentations, please see the following:

Title: Preclinical characterization of the tetravalent NKp46 engager FLEX-NKTM directed against GPC3 (CYT-303) alone or in combination with iPSC-derived Natural Killer (iNK) cells against hepatocellular carcinoma (HCC)
Presenter: Antonio Arulanandam
Session Title: Adoptive Cellular Therapy
Date and time of the session: Tuesday, April 12, 2022, from 9:00 a.m. to 12:30 p.m.
Location: New Orleans Convention Center, DH Exhibit Halls, Poster Section 30
Billboard number: 8
Permanent abstract number: 2752
abstract link

Title: Novel CD38 NKp46 FLEX NKTM multifunctional tetravalent engagers actively target and kill multiple myeloma cells
Presenter: Liang Lin
Session title: Combined immunotherapies / Therapeutic antibodies
Date and time of the session: Tuesday, April 12, 2022, 1:30 p.m. – 5:00 p.m.
Location: New Orleans Convention Center, DH Exhibit Halls, Poster Section 32
Billboard number: 17
Permanent abstract number: 3436
abstract link

About Cytovia Therapeutics
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing many of the most challenging unmet medical needs in cancer. Cytovia is focused on harnessing the innate immune system by developing complementary and disruptive NK cell and NK-engaging antibody platforms. The company is developing three types of iPSC-derived (or iNK) cells: unedited iNK cells, TALEN® gene-modified iNK cells with improved function and persistence, and TALEN® gene-modified iNK cells with chimeric antigen receptors (CAR-iNK) to improve specific tumor targeting. The second complementary core technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology.

These two technology platforms are used to develop treatments for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma.

Based in Aventura, Florida, Cytovia has research and development labs in Natick, Massachusetts, and a GMP cell manufacturing facility in Puerto Rico. The company’s R&D work is complemented by scientific partnerships with Cellectis, CytoImmune, Hebrew University of Jerusalem, INSERM, New York Stem Cell Foundation and University of California, San Francisco (UCSF).

Cytovia recently formed CytoLynx Therapeutics, a strategic partnership focused on research and development, manufacturing and commercialization activities in Greater China and beyond.

Learn more about www.cytoviatx.com and follow us on Facebook, Twitter, LinkedIn, Youtubeand instagram.

About GPC3
Glypican-3 (GPC3) is a cell surface heparan sulfate proteoglycan. It is expressed in the liver and kidneys of fetuses but is poorly expressed in adults, except in the placenta. However, it is highly expressed in HCC and other pediatric and adult solid tumors. GPC3 promotes Wnt-dependent cell proliferation and has been strongly suggested to be linked to malignant transformation of HCC, making it a promising target for cancer immunotherapy.

About CD38
Differentiation cluster 38 (CD38) is a type II receptor membrane glycoprotein that plays a role in cell adhesion, migration, and signal transduction. Moreover, CD38 is an ectoenzyme involved in the generation of nucleotide metabolites, such as ADP-ribose which regulate cellular metabolism. CD38 is highly expressed in multiple myeloma (MM) on malignant plasma cells and is also moderately expressed on normal T, B, NK and myeloid cells. Antibodies targeting CD38, such as daratumumab and isatuximab, are FDA-approved for the treatment of MM as monotherapy and in combination.

THE SOURCE: Cytovia therapeutics